DK3160948T3 - BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS - Google Patents

BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS Download PDF

Info

Publication number
DK3160948T3
DK3160948T3 DK15736015.7T DK15736015T DK3160948T3 DK 3160948 T3 DK3160948 T3 DK 3160948T3 DK 15736015 T DK15736015 T DK 15736015T DK 3160948 T3 DK3160948 T3 DK 3160948T3
Authority
DK
Denmark
Prior art keywords
benzoxazin
dihydro
oxo
mmol
compound
Prior art date
Application number
DK15736015.7T
Other languages
Danish (da)
English (en)
Inventor
Gavin O'mahony
Michael Kossenjans
Karl Edman
Johan Kajanus
Carl Anders Hogner
Philip Cornwall
Andrew Turner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3160948T3 publication Critical patent/DK3160948T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK15736015.7T 2014-06-30 2015-06-26 BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS DK3160948T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
DK3160948T3 true DK3160948T3 (en) 2019-02-18

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15736015.7T DK3160948T3 (en) 2014-06-30 2015-06-26 BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS

Country Status (26)

Country Link
US (2) US10017502B2 (2)
EP (1) EP3160948B1 (2)
JP (1) JP6368383B2 (2)
KR (1) KR102012222B1 (2)
CN (1) CN106536491B (2)
AR (1) AR101036A1 (2)
AU (1) AU2015282450C1 (2)
CA (1) CA2953655C (2)
CY (1) CY1121596T1 (2)
DK (1) DK3160948T3 (2)
EA (1) EA029518B1 (2)
ES (1) ES2707726T3 (2)
HR (1) HRP20190147T1 (2)
HU (1) HUE042370T2 (2)
LT (1) LT3160948T (2)
ME (1) ME03316B (2)
MX (1) MX367404B (2)
PL (1) PL3160948T3 (2)
PT (1) PT3160948T (2)
RS (1) RS58274B1 (2)
SI (1) SI3160948T1 (2)
SM (1) SMT201900039T1 (2)
TR (1) TR201900659T4 (2)
TW (1) TWI677498B (2)
UY (1) UY36195A (2)
WO (1) WO2016001631A1 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367404B (es) * 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
WO2021037400A1 (en) * 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CA3222502A1 (en) 2021-06-15 2022-12-22 Lingyun Wu Benzoxazinone derivatives
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
CR20250112A (es) 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
CN120344508A (zh) * 2022-12-15 2025-07-18 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
AU2003303231A1 (en) * 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
BRPI0513119A (pt) * 2004-07-14 2008-04-29 Ligand Pharm Inc compostos e métodos modulares de receptores intracelulares
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
CA2635541A1 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
SI2089367T1 (sl) 2006-10-31 2012-02-29 Pfizer Prod Inc Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2008118319A2 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
CN101679243B (zh) 2007-04-09 2012-09-26 第一三共株式会社 吡咯衍生物的阻转异构体
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
WO2009154557A1 (en) * 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
US20120022058A1 (en) 2009-04-10 2012-01-26 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
CN102906495B (zh) 2010-05-11 2016-08-24 皇家飞利浦电子股份有限公司 照明模块
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
EP2638012A1 (en) 2010-11-10 2013-09-18 Boehringer Ingelheim International GmbH Pyridyl ureas as mineralocorticoid receptor antagonists
MX367404B (es) * 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Also Published As

Publication number Publication date
TR201900659T4 (tr) 2019-02-21
UY36195A (es) 2016-01-08
ME03316B (me) 2019-10-20
ES2707726T3 (es) 2019-04-04
US9394291B2 (en) 2016-07-19
EA201790046A1 (ru) 2017-08-31
CN106536491A (zh) 2017-03-22
KR20170021883A (ko) 2017-02-28
EA029518B1 (ru) 2018-04-30
MX367404B (es) 2019-08-20
EP3160948A1 (en) 2017-05-03
US20170217945A1 (en) 2017-08-03
AU2015282450A1 (en) 2017-02-02
CY1121596T1 (el) 2020-05-29
KR102012222B1 (ko) 2019-10-21
JP6368383B2 (ja) 2018-08-01
RS58274B1 (sr) 2019-03-29
HRP20190147T1 (hr) 2019-03-22
SMT201900039T1 (it) 2019-02-28
PL3160948T3 (pl) 2019-04-30
AU2015282450B2 (en) 2018-05-10
AU2015282450C1 (en) 2018-09-20
US10017502B2 (en) 2018-07-10
JP2017522300A (ja) 2017-08-10
SI3160948T1 (sl) 2020-06-30
CN106536491B (zh) 2018-12-18
US20150376170A1 (en) 2015-12-31
PT3160948T (pt) 2019-02-01
MX2017000183A (es) 2017-04-25
TWI677498B (zh) 2019-11-21
CA2953655A1 (en) 2016-01-07
TW201613909A (en) 2016-04-16
AR101036A1 (es) 2016-11-16
HUE042370T2 (hu) 2019-06-28
LT3160948T (lt) 2019-02-11
WO2016001631A1 (en) 2016-01-07
CA2953655C (en) 2020-05-12
EP3160948B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
DK3160948T3 (en) BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS
JP7168773B2 (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
AU2016299484B2 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP5564036B2 (ja) ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体
JP6211530B2 (ja) 含窒素複素環化合物
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
KR20180016485A (ko) 무스카린성 m2 수용체의 양성 알로스테릭 조정제
EP2194051B1 (en) Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity
CN105073724A (zh) 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物
EP2501233B1 (en) Quinazoline compounds
AU2019230859B2 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
CA3162126A1 (en) Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
WO2011025798A1 (en) Compounds and methods
IL324619A (en) (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses
HK1237338A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
HK1237338B (en) Benzoxazinone amides as mineralocorticoid receptor modulators
KR20170106483A (ko) 테트라히드로피라닐 벤즈아미드 유도체